The place of the botulinum toxin in the management of multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 112, Issue 7, 2010, Pages 592-596

  Habek, Mario ^a,b   Karni, Arnon ^c,d   Balash, Yakov ^c,d   Gurevich, Tanya ^c,d  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Botulinum toxin; Multiple sclerosis; Spasticity; Symptoms

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; PLACEBO; BOTULINUM TOXIN; MUSCLE RELAXANT AGENT;

ADDUCTOR SPASTICITY; BACKACHE; BLADDER DYSFUNCTION; CERVICAL DYSTONIA; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIARRHEA; DIPLOPIA; DIURNAL ENURESIS; DRUG EFFICACY; DRUG SAFETY; FACIAL MYOKYMIA; FATIGUE; HEADACHE; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; HYPERSALIVATION; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; MYOKYMIA; NOCTURIA; NYSTAGMUS; OSCILLOPSIA; OVERACTIVE BLADDER; PAIN; PHYSIOTHERAPY; PTOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SPASTICITY; STOMACH PARESIS; TINNITUS; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; TRIGEMINUS NEURALGIA; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; WORK CAPACITY; DOSE RESPONSE; MUSCLE SPASTICITY; URINARY BLADDER, NEUROGENIC;

BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PAIN; QUALITY OF LIFE; URINARY BLADDER, NEUROGENIC;

EID: 77955657633     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2010.04.010     Document Type: Review

References (51)

1. T. Henze Managing specific symptoms in people with multiple sclerosis Int MS J 12 2005 60 68
2. J.W. Lance Symposium synopsis R.G. Feldman, R.R. Young, W.P. Koella, Spasticity: disordered motor control Chicago 1980 Year Book Medical Publishers
3. M.E. Gormley Jr., C.F. O'Brien, and S.A. Yablon A clinical overview of treatment decisions in the management of spasticity Muscle Nerve Suppl 6 1997 S14 20
4. B. Bussel, O.R. Neris, and L. Mailhan Spasticity and multiple sclerosis Rev Neurol (Paris) 157 2001 1041 1044
5. D.T. Shakespeare, M. Boggild, and C. Young Anti-spasticity agents for multiple sclerosis Cochrane Database Syst Rev 4 2003 CD001332
6. C. Kabus, M. Hecht, G. Japp, W.H. Jost, D. Pöhlau, and S. Stuckrad-Barre Botulinum toxin in patients with multiple sclerosis J Neurol 253 Suppl. 1 2006 I26 I28
7. B.J. Snow, J.K. Tsui, M.H. Bhatt, M. Varelas, S.A. Hashimoto, and D.B. Calne Treatment of spasticity with botulinum toxin: a double-blind study Ann Neurol 28 1990 512 515
8. J. Borg-Stein, Z.M. Pine, J.R. Miller, and M.F. Brin Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations Am J Phys Med Rehabil 72 1993 364 368
9. J. Finsterer, I. Fuchs, and B. Mamoli Automatic EMG-guided botulinum toxin treatment of spasticity Clin Neuropharmacol 20 1997 195 203
10. N. Hyman, M. Barnes, B. Bhakta, A. Cozens, M. Bakheit, and B. Kreczy-Kleedorfer Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study J Neurol Neurosurg Psychiatry 68 2000 707 712
11. P. Sobolewski The application of botulinum toxin type A in the treatment of spastic paraparesis Przegl Lek 64 Suppl. 2 2007 3 7
12. D.A. Restivo, M. Tinazzi, F. Patti, A. Palmeri, and D. Maimone Botulinum toxin treatment of painful tonic spasms in multiple sclerosis Neurology 61 2003 719 720
13. E.J. Pappert Botulinum toxin type B treatment in multiple sclerosis patients with lower-extremity adductor spasticity: results of a double-blind, placebo-controlled, safety study Arch Phys Med Rehabil 88 2007 E84
14. M. Giovannelli, G. Borriello, P. Castri, L. Prosperini, and C. Pozzilli Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis Clin Rehabil 21 2007 331 337
15. W.H. Jost Botulinum toxin in multiple sclerosis J Neurol 253 Suppl. 1 2006 I16 20
16. Royal College of Physicians British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology/Spasticity in adults: management using botulinum toxin. National guidelines 2009 RCP London pp. 40-7
17. J. Wissel, and T. Entner Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis Wien Klin Wochenschr 113 Suppl. 4 2001 20 24 (Pubitemid 33015388)
18. D. Lamotte, and P. Thoumie Multiple sclerosis and botulinum toxin Ann Readapt Med Phys 46 2003 299 302
19. G. Karsenty, A. Reitz, B. Wefer, S. Boy, and B. Schurch Understanding detrusor sphincter dyssynergia - significance of chronology Urology 66 2005 763 768
20. P. Abrams, L. Cardozo, M. Fall, D. Griffiths, P. Rosier, and U. Ulmsten Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 2002 167 178
21. K.J. Weld, M.J. Graney, and R.R. Dmochowski Clinical significance of detrusor sphincter dyssynergia type in patients with post-traumatic spinal cord injury Urology 56 2000 565 568
22. G.A. Barbalias, G. Nikiforidis, and E.N. Liatsikos Vesicourethral dysfunction associated with multiple sclerosis: clinical and urodynamic perspectives J Urol 160 1998 106 111
23. D.D. Dykstra, and A.A. Sidi Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study Arch Phys Med Rehabil 71 1990 24 26
24. P. Gallien, J.M. Reymann, G. Amarenco, B. Nicolas, M. de Sze, and E. Bellissant Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients J Neurol Neurosurg Psychiatry 76 2005 1670 1676
25. H. Schulte-Baukloh, J. Schobert, T. Stolze, B. Stürzebecher, C. Weiss, and H.H. Knispel Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis Neurourol Urodyn 25 2006 110 115
26. V. Kalsi, G. Gonzales, R. Popat, A. Apostolidis, S. Elneil, and P. Dasgupta Botulinum injections for the treatment of bladder symptoms of multiple sclerosis Ann Neurol 62 2007 452 457
27. I. Ehren, D. Volz, E. Farrelly, L. Berglund, L. Brundin, and C. Hultling Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo controlled, double-blind study Scand J Urol Nephrol 41 2007 335 340
28. E. Lekka, and L.K. Lee Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters Eur Urol 50 2006 806 809
29. S. Beard, A. Hunn, and J. Wight Treatments for spasticity and pain in multiple sclerosis: a systematic review Health Technol Assess 7 40 2003 iii, ix-x, 1-111
30. B. Jabbari Botulinum neurotoxins in the treatment of refractory pain Nat Clin Pract Neurol 4 2008 676 685
31. I. Zadro, B. Barun, M. Habek, and V.V. Brinar Isolated cranial nerve palsies in multiple sclerosis Clin Neurol Neurosurg 110 2008 886 888
32. J. Jankovic, K. Schwartz, W. Clemence, A. Aswad, and J. Mordaunt A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor Mov Disord 11 1996 250 256
33. M.F. Brin, K.E. Lyons, J. Doucette, C.H. Adler, J.N. Caviness, and C.L. Comella A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor Neurology 56 2001 1523 1528
34. R. Pahwa, K. Busenbark, E.F. Swanson-Hyland, R.M. Dubinsky, J.P. Hubble, and C. Gray Botulinum toxin treatment of essential head tremor Neurology 45 1995 822 824
35. M.J. Sedano, J.M. Trejo, J.L. Macarrón, J.M. Polo, J. Berciano, and J. Calleja Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin Eur Neurol 43 2000 137 140
36. R. Murthy, E. Dawson, S. Khan, G.G. Adams, and J. Lee Botulinum toxin in the management of internuclear ophthalmoplegia J AAPOS 11 2007 456 459
37. M.X. Repka, P.J. Savine, and R.D. Rienechke Treatment of acquired nystagmus with botulinum neurotoxin A Arch Ophthalmol 112 1994 1320 1324
38. S.T. Ruben, J.P. Lee, D. O'Neil, I. Dunlop, and J.S. Elston The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia Ophthalmology 101 1994 783 787
39. G. Lennerstrand, O.A. Nordbø, S. Tian, B. Eriksson-Derouet, and T. Ali Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications Acta Ophthalmol Scand 76 1998 27 37
40. J.K. Curé, L.D. Cromwell, J.L. Case, G.D. Johnson, and F.E. Musiek Auditory dysfunction caused by multiple sclerosis: detection with MR imaging AJNR Am J Neuroradiol 11 1990 817 820
41. K.R. Stidham, P.H. Solomon, and J.B. Roberson Evaluation of botulinum toxin A in treatment of tinnitus Otolaryngol Head Neck Surg 132 2005 883 889
42. G. Cruccu, A. Biasiotta, S. Di Rezze, M. Fiorelli, F. Galeotti, and P. Innocenti Trigeminal neuralgia and pain related to multiple sclerosis Pain 43 2009 186 191
43. E.J. Piovesan, H.G. Teive, P.A. Kowacs, M.V. Della Coletta, L.C. Werneck, and S.D. Silberstein An open study of botulinum-A toxin treatment of trigeminal neuralgia Neurology 65 2005 306 308
44. S. Raghav, D. Kipp, J. Watson, and W. Spring Gastroparesis with multiple sclerosis Mult Scler 12 2006 243 244
45. J. Arts, L. Holvoet, P. Caenepeel, R. Bisschops, D. Sifrim, and K. Verbeke Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis Aliment Pharmacol Ther 26 2007 1251 1258
46. F.K. Friedenberg, A. Palit, H.P. Parkman, A. Hanlon, and D.B. Nelson Botulinum toxin A for the treatment of delayed gastric emptying Am J Gastroenterol 103 2008 416 423
47. K. Irani, L. Rodriguez, D.P. Doody, and A.M. Goldstein Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction Pediatr Surg Int 24 2008 779 783
48. E. Varghese-Kroll, and E.P. Elovic Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity Am J Phys Med Rehabil 88 June (6) 2009 495 499
49. K.P. Bhatia, A. Münchau, P.D. Thompson, M. Houser, V.S. Chauhan, and M. Hutchinson Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases J Neurol Neurosurg Psychiatry 67 1999 90 93
50. G. Kobelt, J. Berg, P. Lindgren, S. Fredrikson, and B. Jönsson Costs and quality of life of patients with multiple sclerosis in Europe J Neurol Neurosurg Psychiatry 77 2006 918 926 (Pubitemid 44174075)
51. A. Esquenazi Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity Eur J Neurol 13 December (Suppl. 4) 2006 27 34